[1] Natarajan P, O'Donnell C J. Reducing cardiovascular risk using genom-ic information in the era of precision medicine[J]. Circulation, 2016, 133(12):1155-1159.
[2] Siva N. UK gears up to decode 100000 genomes from NHS patients[J]. Lancet, 2015, 385(9963):103-104.
[3] Wang Y, Zhao X, Lin J, et al. Association between CYP2C19 loss-offunction allele status and efficacy of clopidogrel for risk reduction among patients with minor stroke or transient ischemic attack[J]. JA-MA, 2016, 316(1):70-78.
[4] Jiang L, Krumholz H M, Li X, et al. Achieving best outcomes for pa-tients with cardiovascular disease in China by enhancing the quality of medical care and establishing a learning health-care system[J]. Lancet, 2015, 386(10002):1493-1505.
[5] Yang G, Wang Y, Zeng Y, et al. Rapid health transition in China, 1990-2010:Findings from the Global Burden of Disease Study 2010[J]. Lancet, 2013, 381(9882):1987-2015.
[6] Goldberger J J, Buxton A E. Personalized medicine vs guideline-based medicine[J]. JAMA, 2013, 309(24):2559-2560.
[7] Sheridan D J, Julian D G. Achievements and limitations of evidencebased medicine[J]. Journal of the American College of Cardiology, 2016, 68(2):204-213.
[8] Ference B A, Majeed F, Penumetcha R, et al. Effect of naturally ran-dom allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both:A 2×2 factorial Mendelian randomization study[J]. Journal of the American College of Cardiology, 2015, 65(15):1552-1561.
[9] Khetarpal S A, Qamar A, Millar J S, et al. Targeting ApoC-Ⅲ to re-duce coronary disease risk[J]. Current Atherosclerotic Report, 2016, 18(9):54.
[10] Ortiz-Genga M F, Cuenca S, Dal Ferro M, et al. Truncating FLNC mu-tations are associated with high-risk dilated and arrhythmogenic car-diomyopathies[J]. Journal of the American College of Cardiology, 2016, 68(22):2440-2451.
[11] Chida A, Inai K, Sato H, et al. Prognostic predictive value of gene mu-tations in Japanese patients with hypertrophic cardiomyopathy[J]. Heart Vessels, 2017, 32(6):700-707.
[12] Lindsey M L, Mayr M, Gomes A V, et al. Transformative impact of proteomics on cardiovascular health and disease:A scientific state-ment from the american heart association[J]. Circulation, 2015, 132(9):852-872.
[13] Wang Z, Klipfell E, Bennett B J, et al. Gut flora metabolism of phos-phatidylcholine promotes cardiovascular disease[J]. Nature, 2011, 472(7341):57-63.
[14] Santisteban M M, Qi Y, Zubcevic J, et al. Hypertension-linked patho-physiological alterations in the gut[J]. Circulation Research, 2017, 120(2):312.
[15] Kelly T N, Bazzano L A, Ajami N J, et al. Gut microbiome associates with lifetime cardiovascular disease risk profile among bogalusa heart study participants[J]. Circulation Research, 2016, 119(8):956-964.
[16] Shah S J, Katz D H, Selvaraj S, et al. Phenomapping for novel classifi-cation of heart failure with preserved ejection fraction[J]. Circulation, 2015, 131(3):269-279.
[17] MacRae C A, Vasan R S. The future of genetics and genomics:Clos-ing the phenotype gap in precision medicine[J]. Circulation, 2016, 133(25):2634-2639.
[18] Benjamin I, Brown N, Burke G, et al. American heart association car-diovascular genome-phenome study:Foundational basis and program[J]. Circulation, 2015, 131(1):100-112.
[19] Moss A J, Shimizu W, Wilde A A, et al. Clinical aspects of type-1 long-QT syndrome by location, coding type, and biophysical function of mutations involving the KCNQ1 gene[J]. Circulation, 2007, 115(19):2481-2489.
[20] Boycott K M, Vanstone M R, Bulman D E, et al. Rare-disease genet-ics in the era of next-generation sequencing:Discovery to translation[J]. Nature Review Genetics, 2013, 14(10):681-691.
[21] Chong J X, Buckingham K J, Jhangiani S N, et al. The genetic basis of mendelian phenotypes:Discoveries, challenges, and opportunities[J]. American Journal of Human Genetics, 2015, 97(2):199-215.
[22] 冯时, 弓孟春, 张抒扬. 中国国家罕见病注册系统及其队列研究:愿景与实施路线[J]. 中华内分泌代谢杂志, 2016, 32(12):977-982. Feng Shi, Gong mengchun, Zhang Shuyang. The national rare diseases registry system of China and the related cohorts studies:Vision and roadmap[J]. Chinese Journal of Endocrinology and Metabolism, 2016, 32(12):977-982.
[23] Sabatine M S, Giugliano R P, Keech A C, et al. Evolocumab and clini-cal outcomes in patients with cardiovascular disease[J]. New England Journal of Medicine, 2017, 2017(376):1713-1722.
[24] Harper A R, Topol E J. Pharmacogenomics in clinical practice and drug development[J]. Nature Biotechnology, 2012, 30(11):1117-1124.
[25] Nelson M R, Johnson T, Warren L, et al. The genetics of drug effica-cy:Opportunities and challenges[J]. Nature Review Genetics, 2016, 17(4):197-206.
[26] Piepoli M F, Hoes A W, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice:The Sixth Joint Task Force of the European Society of Cardiology and Other So-cieties on Cardiovascular Disease Prevention in Clinical Practice (con-stituted by representatives of 10 societies and by invited experts) De-veloped with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)[J]. European Heart Journal, 2016, 37(29):2315-2381.
[27] Khera A V, Emdin C A, Drake I, et al. Genetic risk, adherence to a healthy lifestyle, and coronary disease[J]. New England Journal of Medicine, 2016, 375(24):2349-2358.
[28] Kullo I J, Jouni H, Austin E E, et al. Incorporating a genetic risk score into coronary heart disease risk estimates:Effect on low-density lipoprotein cholesterol levels (the MI-GENES clinical trial)[J]. Circula-tion, 2016, 133(12):1181-1188.
[29] Warren H R, Evangelou E, Cabrera C P, et al. Genome-wide associa-tion analysis identifies novel blood pressure loci and offers biological insights into cardiovascular risk[J]. Nature Genetics, 2017, 49(3):403-415.
[30] Weintraub R G, Semsarian C, Macdonald P. Dilated cardiomyopathy[J]. Lancet, 2017, 390(10092):400-414.
[31] Piran S, Liu P, Morales A, et al. Where genome meets phenome:ratio-nale for integrating genetic and protein biomarkers in the diagnosis and management of dilated cardiomyopathy and heart failure[J]. Jour-nal of the American College of Cardiology, 2012, 60(4):283-289.
[32] Beckermann T M, McLeod K, Murday V, et al. Novel SCN5A muta-tion in amiodarone-responsive multifocal ventricular ectopy-associat-ed cardiomyopathy[J]. Heart Rhythm, 2014, 11(8):1446-1453.
[33] Roberts A M, Ware J S, Herman D S, et al. Integrated allelic, tran-scriptional, and phenomic dissection of the cardiac effects of titin trun-cations in health and disease[J]. Science Translational Medicine, 2015, 7(270):270ra6-ra6.
[34] Kaufman A L, Spitz J, Jacobs M, et al. Evidence for clinical implemen-tation of pharmacogenomics in cardiac drugs[J]. Mayo Clin Proceed-ings, 2015, 90(6):716-729.
[35] Johnson J A, Cavallari L H. Pharmacogenetics and cardiovascular dis-ease——implications for personalized medicine[J]. Pharmacology Re-views, 2013, 65(3):987-1009.
[36] Aminkeng F, Bhavsar A P, Visscher H, et al. A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer[J]. Nature Genetics, 2015, 47(9):1079-1084.
[37] Scott S A, Sangkuhl K, Gardner E E, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19(CYP2C19) genotype and clopidogrel therapy[J]. Clinica Pharmacologi-cal Therapy, 2011, 90(2):328-332.
[38] Caudle K E, Klein T E, Hoffman J M, et al. Incorporation of pharma-cogenomics into routine clinical practice:The Clinical Pharmacogenet-ics Implementation Consortium (CPIC) guideline development process[J]. Current Drug Metabolism, 2014, 15(2):209-217.
[39] Johnson J A, Gong L, Whirl-Carrillo M, et al. Clinical pharmacogenet-ics implementation consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing[J]. Clinical Pharmacological Therapy, 2011, 90(4):625-629.
[40] Jang J S, Cho K I, Jin H Y, et al. Meta-analysis of cytochrome P4502C19 polymorphism and risk of adverse clinical outcomes among coro-nary artery disease patients of different ethnic groups treated with clopidogrel[J]. American Journal of Cardiology, 2012, 110(4):502-508.
[41] Swen J J, Nijenhuis M, de Boer A, et al. Pharmacogenetics:From bench to byte——an update of guidelines[J]. Clinical Pharmacological Therapy 2011, 89(5):662-673.
[42] Rasmussen-Torvik L J, Stallings S C, Gordon A S, et al. Design and anticipated outcomes of the eMERGE-PGx project:A multicenter pi-lot for preemptive pharmacogenomics in electronic health record sys-tems[J]. Clinical Pharmacological Therapy, 2014, 96(4):482-489.
[43] Mehta C, Gao P, Bhatt D L, et al. Optimizing trial design:Sequential, adaptive, and enrichment strategies[J]. Circulation, 2009, 119(4):597-605.
[44] Sherman R E, Anderson S A, Dal Pan G J, et al. Real-world evi-dence:What is it and what can it tell us?[J]. New England Journal of Medicine, 2016, 375(23):2293-2297.
[45] Ni Y, Wright J, Perentesis J, et al. Increasing the efficiency of trialpatient matching:Automated clinical trial eligibility pre-screening for pediatric oncology patients[J]. BMC Medicine Informatics and Deci-sion Making, 2015, 15(1):28.
[46] Schork N J. Personalized medicine:Time for one-person trials[J]. Na-ture, 2015, 520(7549):609-611.
[47] Raal F J, Stein E A, Dufour R, et al. PCSK9 inhibition with evolocum-ab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTH-ERFORD-2):A randomised, double-blind, placebo-controlled trial[J]. Lancet, 2015, 385(9965):331-340.
[48] Antman E M, Loscalzo J. Precision medicine in cardiology[J]. Nature Review Cardiology, 2016, 13(10):591-602.
[49] Desai A S, Bhimaraj A, Bharmi R, et al. Reduction in heart failure hospitalizations with ambulatory hemodynamic monitoring seen in clin-ical trials is maintained in the 'real world'[J]. Journal of the American College of Cardiology, 2017, 69(19):2357-2365.
[50] Najafzadeh M, Schneeweiss S. From trial to target populations:Cali-brating real-world data[J]. New England Journal of Medicine, 2017, 376(13):1203-1205.
[51] Goldfeder R L, Priest J R, Zook J M, et al. Medical implications of technical accuracy in genome sequencing[J]. Genome Medicine, 2016, 8(1):24.
[52] Chaussabel D, Pulendran B. A vision and a prescription for big dataenabled medicine[J]. Nature Immunology, 2015, 16(5):435-439.
[53] 弓孟春, 马永慧, 张玢, 等. 精准医学对我国医学伦理学的挑战与应对策略初步探讨[J]. 中华医学杂志, 2017, 97(19):1446-1449. Gong Mengchun, Ma Yonghui, Zhang Fen, et al. The challenges and strategies of ethical in precision medicine in China[J]. National Medi-cal Journal of China, 2017, 97(19):1446-1449.
[54] Joyner M J, Paneth N. Seven questions for personalized medicine[J]. Journal of the American Medical Association, 2015, 314(10):999-1000.
[55] Savage N. Privacy:The myth of anonymity[J]. Nature, 2016, 537(7619):S70-S72.
